Volkova Maria, Khochenkov Dmitry, Olshanskaya Anna, Khochenkova Yulia, Solomko Elyso, Ashuba Saida, Tsimafeyeu Ilya
FSBI N.N. Blokhin National Medical Research Center for Oncology, Moscow, Russian Federation.
Togliatti State University, Togliatti, Russian Federation.
Urol Res Pract. 2025 May 21;51(1):7-11. doi: 10.5152/tud.2025.24154.
Objective: This study aimed to assess the expression of platelet-derived growth factor receptors alpha and beta (PDGFR!/") in primary tumor cells of patients with renal cell carcinoma (RCC). Methods: Platelet-derived growth factor receptors alpha and beta expression was analyzed in RCC specimens from 65 RCC patients (pT1a-T4NanyMany) using immunohis- tochemistry. Expression levels were quantified using the semi-quantitative H-score (HS) method, and correlations between PDGFR!/" expression and tumor characteris- tics were evaluated. The impact of PDGFR!/" expression on patient survival was also examined. Results: Platelet-derived growth factor receptor alpha was expressed in the cytoplasm and membrane of 58.5% of primary RCC cells, with an HS of 62.9 ± 8.4, significantly higher than PDGFR" expression (44.6%; 26.6 ± 5.3; P > .05). Platelet-derived growth factor receptor alpha expression correlated with tumor grade (r = 0.471; P < .0001) and the pN+ category (r = 0.280; P = .024). Platelet-derived growth factor receptor beta expression correlated with tumor grade (r = 0.286; P = .021), venous tumor thrombosis (r = 0.263; P = .034), M+ category (r = 0.305; P = .014), and adrenal metastases (r = 0.306; P = .041). Neither PDGFR! nor PDGFR" expression levels influenced patient survival. Conclusion: Platelet-derived growth factor receptor alpha was more highly expressed in RCC cells compared to PDGFR". Overexpression of PDGFR!/" was associated with higher tumor grade and advanced RCC stages, though it did not affect patient survival.
本研究旨在评估肾细胞癌（RCC）患者原发性肿瘤细胞中血小板衍生生长因子受体α和β（PDGFRα/β）的表达情况。方法：采用免疫组织化学方法分析65例RCC患者（pT1a - T4NanyMany）的RCC标本中血小板衍生生长因子受体α和β的表达。使用半定量H评分（HS）法对表达水平进行量化，并评估PDGFRα/β表达与肿瘤特征之间的相关性。还检测了PDGFRα/β表达对患者生存的影响。结果：58.5%的原发性RCC细胞的细胞质和细胞膜中表达血小板衍生生长因子受体α，HS为62.9±8.4，显著高于PDGFRβ的表达（44.6%；26.6±5.3；P＞0.05）。血小板衍生生长因子受体α的表达与肿瘤分级（r = 0.471；P＜0.0001）和pN+类别（r = 0.280；P = 0.024）相关。血小板衍生生长因子受体β的表达与肿瘤分级（r = 0.286；P = 0.021）、肿瘤静脉血栓形成（r = 0.263；P = 0.034）、M+类别（r = 0.305；P = 0.014）和肾上腺转移（r = 0.306；P = 0.041）相关。PDGFRα和PDGFRβ的表达水平均不影响患者生存。结论：与PDGFRβ相比，血小板衍生生长因子受体α在RCC细胞中的表达更高。PDGFRα/β的过表达与更高的肿瘤分级和晚期RCC分期相关，尽管它不影响患者生存。
